Development and validation of a novel Endoscopic ulcer Activity Score for Evaluation of Crohn's Disease (EASE-CD) using data from two randomised controlled trials
Christopher Ma(University of Calgary), Vipul Jairath(Western University), Julie Rémillard, Bruce E. Sands(Icahn School of Medicine at Mount Sinai), Rupert W. Leong(The University of Sydney), Reena Khanna(University of Toronto), Lisa M. Shackelton, Bryan Maguire, Ailsa Hart(St Mark's Hospital), Pieter Hindryckx(Ghent University Hospital), Silvio Danese(IRCCS Ospedale San Raffaele), Brian G. Feagan(Western University), David T. Rubin(University of California System), Geert D’Haens(Amsterdam University Medical Centers), Brian Bressler(University of British Columbia), Guangyong Zou(Western University), Miles Sparrow(Alfred Health), Mahmoud Mosli(King Abdulaziz University), Laurent Peyrin-Biroulet(Inserm), Remo Panaccione(University of Calgary)
Cited by 6
Related Papers
Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease
|Nature|2012|4.8k
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment
|Genome biology|2012|2.8k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k